# Stoic VC

> Stoic VC is a VC fund in Sydney backing Biotechnology and Medical. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Sydney, Australia
- Total investments: 24
- Last investment: Oct 2025
- Lead investor: 4%
- Last updated: Aug 2026
- LinkedIn: https://au.linkedin.com/company/stoic-venture-capital
- Website: https://stoicvc.com.au

Stoic VC is a VC fund in Sydney focused on Biotechnology and Medical. Investing at the frontier of research innovation.

## Contacts

5 contacts available for Stoic VC. Shizune tracks 5 team members at Stoic VC. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/stoic-vc-269b?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $600k–$4.2M |
| Series A | $7.6M–$16M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 29% |
| Medical | 4 | 17% |
| Health Care | 4 | 17% |
| Software | 3 | 13% |
| Biopharma | 3 | 13% |

40 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 9 | 38% |
| Funding Round | 6 | 25% |
| Series A | 4 | 17% |
| Series B | 2 | 8% |
| Series C | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Australia | 16 | 67% |
| United States | 1 | 4% |
| United Kingdom | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Fiona Zhuang | General Partner | 0 | https://shizune.co/investors/profile/fiona-zhuang-2f5d |
| Geoff Waring | Co-Founder & Managing Partner | 0 | https://shizune.co/investors/profile/geoff-waring |
| Guy Hedley | Co-Founder & General Partner | 0 | https://shizune.co/investors/profile/guy-hedley |
| Harikesh Pushpapathan | Portfolio Manager | 0 | https://shizune.co/investors/profile/harikesh-pushpapathan |
| Jade Bao | Partner | 0 | https://shizune.co/investors/profile/jade-bao |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ena Respiratory | Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $22.4M | Series B | Oct 22, 2025 |  |
| Kinoxis Therapeutics | Kinoxis Therapeutics is an early stage biotechnology company based in Australia that is working to progress the development of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company has licensed these compounds from the University of Sydney, with the lead candidate demonstratingpotent anti-addictive and prosocial effects in a number of different animal models and is progressing through pre-clinical testing. | $9.5M | Series B | Aug 12, 2024 |  |
| Lenexa Medical | Lenexa Medical is an Australian based MedTech company. | $1M | Seed | Feb 03, 2023 |  |
| BioScout | BioScout utilises state-of-the-art technology to detect and prevent airborne diseases allowing for proactive disease management on farms worldwide! | $1.2M | Seed | Jun 20, 2022 |  |
| LM Plus | LM Plus is an operator of a technology company intended to develop unique liquid metal-based technology. | $600K | Seed | Aug 02, 2021 |  |
| Ena Respiratory | Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $24.2M | Venture - Series Unknown | Jun 17, 2021 |  |
| Ena Respiratory | Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $7.6M | Series A | Sep 28, 2020 |  |
| Wildlife Drones | Wildlife Drones has developed the world’s most innovative animal radio-tracking system using drones so you can track your radio-tagged animals like never before. With over 25 years experience undertaking ecological and scientific animal research, they understand the immense frustration when trying to track the movements of highly mobile animals.Receiving clear signals from radio-tagged animals can be difficult to achieve and is often a very labour intensive and expensive process. The main issue is height. When using hand-held radio-tracking from the ground, you often have to get the antenna as high as possible in order to improve signal detection. This often means finding higher ground, or even hiring helicopters or planes to get the slightest “ping” of a distant radio-tag. Unfortunately, it also often results in losing track of the precious animals you have worked so very hard to tag in order to understand their movements. |  |  | Dec 23, 2019 |  |
| OccuRx | OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis. |  | Series A | Nov 15, 2019 |  |
| Morse Micro | Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com | $15.5M | Series A | May 28, 2019 |  |

10 of 24 investments shown.

## Co-investors
- [Uniseed](https://shizune.co/investors/profile/uniseed-vc) — VC Fund, 21 deals together
- [Uniseed Ventures](https://shizune.co/investors/profile/uniseed-pty) — VC Fund, 18 deals together
- [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners) — VC Fund, 8 deals together
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund, 2 deals together
- [AustralianSuper](https://shizune.co/investors/profile/australiansuper) — VC Fund, 1 deal together
- [Avicella Capital](https://shizune.co/investors/profile/avicella-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [All Investors in Australia](https://shizune.co/investors/investors-australia)
- [All VC Funds in Australia](https://shizune.co/investors/vc-funds-australia)
- [All VC Funds in Oceania](https://shizune.co/investors/vc-funds-oceania)
- [Transportation Investors in Australia](https://shizune.co/investors/transportation-investors-australia)
- [Transportation VC Funds in Australia](https://shizune.co/investors/transportation-vc-funds-australia)
- [Biotech Investors in Australia](https://shizune.co/investors/biotech-investors-australia)

## FAQ

### What does Stoic VC invest in?

Stoic VC invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Funding Round stage. Most of the 24 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Stoic VC's check size?

Stoic VC typically joins rounds of $600k–$4.2M at Seed and $7.6M–$16M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Stoic VC participates in.

### How do I contact Stoic VC?

Public channels for Stoic VC include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Stoic VC?

The team at Stoic VC includes Fiona Zhuang (General Partner), Geoff Waring (Co-Founder & Managing Partner) and Guy Hedley (Co-Founder & General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co